Medical Transcription Billing (MTBC) Receiving Somewhat Positive Media Coverage, Analysis Finds

News articles about Medical Transcription Billing (NASDAQ:MTBC) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Medical Transcription Billing earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave news headlines about the technology company an impact score of 46.495444173163 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the headlines that may have impacted Accern Sentiment’s scoring:

Medical Transcription Billing (NASDAQ MTBC) traded up $0.06 on Tuesday, hitting $2.96. 338,000 shares of the company were exchanged, compared to its average volume of 1,183,226. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.15 and a current ratio of 1.15. Medical Transcription Billing has a 52 week low of $0.29 and a 52 week high of $5.44.

A number of research analysts recently weighed in on the stock. ValuEngine cut shares of Medical Transcription Billing from a “hold” rating to a “sell” rating in a research note on Monday. Zacks Investment Research upgraded shares of Medical Transcription Billing from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Wednesday, August 16th. Finally, Chardan Capital lifted their target price on shares of Medical Transcription Billing from $2.25 to $2.75 and gave the company a “buy” rating in a research note on Tuesday, November 14th.

In other news, CEO Mahmud Ul Haq bought 30,000 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were bought at an average price of $2.93 per share, for a total transaction of $87,900.00. Following the purchase, the chief executive officer now owns 5,017,070 shares in the company, valued at $14,700,015.10. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Stephen Andrew Snyder sold 50,000 shares of Medical Transcription Billing stock in a transaction on Monday, November 6th. The shares were sold at an average price of $3.18, for a total transaction of $159,000.00. Following the transaction, the president now owns 106,000 shares in the company, valued at approximately $337,080. The disclosure for this sale can be found here. 53.70% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “Medical Transcription Billing (MTBC) Receiving Somewhat Positive Media Coverage, Analysis Finds” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.chaffeybreeze.com/2017/12/05/medical-transcription-billing-mtbc-receiving-somewhat-positive-media-coverage-analysis-finds.html.

About Medical Transcription Billing

Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company’s offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform.

Insider Buying and Selling by Quarter for Medical Transcription Billing (NASDAQ:MTBC)

Receive News & Ratings for Medical Transcription Billing Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Transcription Billing Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply